Publicacións en colaboración con investigadores/as de Hospital Universitario La Paz (32)

2024

  1. Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes

    Journal of Infectious Diseases, Vol. 229, Núm. 6, pp. 1796-1802

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  3. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

  4. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe

    Clinical Infectious Diseases, Vol. 76, Núm. 9, pp. 1628-1635

  5. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021

    Journal of Medical Virology, Vol. 95, Núm. 12

2021

  1. Hepatitis C reflex testing in Spain in 2019: A story of success

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 3, pp. 119-126

  2. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

    Nature, Vol. 595, Núm. 7869, pp. 707-712

  3. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000–2016)

    Journal of Infection, Vol. 81, Núm. 4, pp. 600-606

  2. Hospital admissions in individuals with HTLV-1 infection in Spain

    AIDS, Vol. 34, Núm. 7, pp. 1019-1027

  3. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300

2019

  1. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1357-1362

  2. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  3. Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 4, pp. 231-238

  4. Occult hepatitis B and HIV infection

    European Journal of Gastroenterology and Hepatology, Vol. 31, Núm. 11, pp. 1403-1407

  5. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

    The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700

2018

  1. Decline and changing profile of hepatitis delta among injection drug users in Spain

    Antiviral Therapy, Vol. 23, Núm. 1, pp. 87-90

  2. Hepatitis Delta Enters a New Therapeutic Era

    Journal of Infectious Diseases

  3. Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain

    European Journal of Gastroenterology and Hepatology, Vol. 30, Núm. 9, pp. 1060-1062